NASDAQ:XERS Xeris Biopharma Q1 2025 Earnings Report $4.38 +0.22 (+5.29%) Closing price 04:00 PM EasternExtended Trading$4.46 +0.09 (+1.94%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Xeris Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.07Beat/MissN/AOne Year Ago EPSN/AXeris Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$57.61 millionBeat/MissN/AYoY Revenue GrowthN/AXeris Biopharma Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Remove Ads Xeris Biopharma Earnings HeadlinesXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 15, 2025 | Paradigm Press (Ad)12 Best Stocks to Invest in for a Stock Market GameMarch 20, 2025 | insidermonkey.comXeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market GameMarch 19, 2025 | insidermonkey.comCalculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 18, 2025 | finance.yahoo.comSee More Xeris Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xeris Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your email. Email Address About Xeris BiopharmaXeris Biopharma (NASDAQ:XERS), a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.View Xeris Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Upcoming Earnings ASML (4/16/2025)CSX (4/16/2025)Abbott Laboratories (4/16/2025)Kinder Morgan (4/16/2025)Prologis (4/16/2025)Travelers Companies (4/16/2025)U.S. Bancorp (4/16/2025)Netflix (4/17/2025)American Express (4/17/2025)Blackstone (4/17/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
